Apellis Pharmaceuticals

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Apellis Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#714 of 15,742 sponsors by registered trial count).

21 total trials 2 currently recruiting 13 completed top decile by trial count

Apellis Pharmaceuticals: 21 sponsored US clinical trials, 2 recruiting.

Apellis Pharmaceuticals sponsors 21 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 13 completed. 8 of these trials are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Membranoproliferative Glomerulonephritis, with 2 trials.

Top-decile sponsor footprint

Apellis Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#714 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 56/100

13 of 15 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

21 total, page 1 of 1

RECRUITING Phase 2

A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio

NCT07215390
RECRUITING Phase 2

A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT04901936
ACTIVE NOT RECRUITING

A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

NCT06161584
ACTIVE NOT RECRUITING Phase 3

An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

NCT05809531
ACTIVE NOT RECRUITING Phase 2

Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN

NCT04572854
ACTIVE NOT RECRUITING Phase 3

Pegcetacoplan Long Term Safety and Efficacy Extension Study

NCT03531255
COMPLETED Phase 3

Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe

NCT07214740
COMPLETED Phase 3

Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

NCT05067127
COMPLETED Phase 3

An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD

NCT04770545
TERMINATED Phase 2

MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)

NCT04579666
COMPLETED Phase 1

A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19

NCT04402060
COMPLETED Phase 1

Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic Atrophy

NCT03777332
COMPLETED Phase 3

Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration

NCT03525600
COMPLETED Phase 3

A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration

NCT03525613
COMPLETED Phase 3

Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT03500549
COMPLETED Phase 2

Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies

NCT03453619
TERMINATED Phase 1

Pegcetacoplan (APL-2) in Neovascular AMD

NCT03465709
COMPLETED Phase 2

Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)

NCT03226678
COMPLETED Phase 2

Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy

NCT02503332
COMPLETED Phase 1

A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH

NCT02264639
COMPLETED Phase 1

Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD

NCT02461771

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 7
Phase 3 8

Therapeutic Areas

Membranoproliferative Glomerulonephritis 2
Dense Deposit Disease 2
Complement 3 Glomerulopathy (C3G) 2
Complement 3 Glomerulopathy 2
C3 Glomerulonephritis 2
IC-MPGN 2
C3G 2
Geographic Atrophy 2
C3 Glomerulopathy 2
Severe Acute Respiratory Syndrome 1

What is open in the Apellis Pharmaceuticals pipeline

2 recruiting of 21 indexed (10% open); 13 completed (62%).

Phase mix: 8 late (III/IV) vs 12 early (I/II) (balanced across stages).

Top condition: Membranoproliferative Glomerulonephritis (2 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Apellis Pharmaceuticals: open-pipeline peers nationwide

Peers matched on 21 registered trials and 10% open enrollment, not the therapeutic-area sidebar.

Apellis Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 020406080100120 0%5%10%15%20% Total trials Recruiting share Apellis PharmaceuticalsAEterna ZentarisAmphastar PharmaceuticalsArray Biopharma, now a wholly owned subsidiary of PfizerBasilea PharmaceuticaHologicSouthern Illinois UniversityJoslin Diabetes CenterCorewell Health East
Apellis Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Apellis Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 21 trials (± recruiting share)

Sponsors near 10% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Apellis Pharmaceuticals page

21 registered trials is a research-attention snapshot, not an endorsement of Apellis Pharmaceuticals or any single study.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Apellis Pharmaceuticals pipeline card: 21 registered trials from official public datasets.Report a data error.